This just made the news here:
fiercepharma.com/story/glax...
FDA nod for blockbuster COPD hopeful Anoro Ellipta
"...GlaxoSmithKline's ($GSK) respiratory franchise got a boost from the FDA Wednesday, and not a moment too soon. The agency green-lighted its COPD treatment Anoro Ellipta just as a generic of Glaxo's top-selling Advair won its first approval--a reminder that competition for the lung giant may be just around the corner.
According to GSK, Anoro now becomes the first once-daily COPD treatment in the U.S. to combine two drugs that relax airways in a single inhaler. And that's a coup; Anoro beat out treatments still in development at companies like Novartis ($NVS) and Forest Labs ($FRX). Partner Theravance ($THRX) will now turn over a $30 million milestone payment to Glaxo, with another $30 million scheduled for after Anoro's U.S. launch; Glaxo says it plans to begin the rollout early next year..."